Novo Nordisk Signs $1.3 Billion Deal With Nanexa as Shares Fall on Investor Concerns
Novo Nordisk signs a deal with Nanexa for drug delivery technology while shares fall after CEO Mike Doustdar fails to provide concrete turnaround plans to investors.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story · 15 more published before price tracking began
Price data
| Time | Chance of yes |
|---|---|
| now | 15% |
| 27 Sept, 11:33 UTC | 15% |
| 27 Sept, 04:45 UTC | 14% |
| 26 Sept, 16:48 UTC | 12% |
| 26 Sept, 15:48 UTC | 15% |
| 24 Sept, 05:29 UTC | 7% |
Replay the odds, article by article
Step through each article in the order it published and watch Eli Lilly respond.
The story so far
7 publishers have covered this in 20 articles since 20 Sept 2026. International homepage published first, on 20 September at 04:00 UTC; MarketWatch followed 28h 58m later. The most recent article, from Quartz, appeared on 25 September at 13:50 UTC.
Outlets reporting it: News Feed (major outlet), Bloomberg.com (major outlet), CNBC (major outlet), MarketWatch, STAT, Quartz, Fortune.
One prediction market prices this story:
- Eli Lilly — the market puts it at 15%, with $493 traded in the last 24 hours, closing 1 Jan 2027. The outcome is Yes if the U.S. federal government takes any financial stake in Eli Lilly before January 1, 2027. Otherwise, the outcome is No. Readers often mistake the linked news story about Novo Nordisk for a relevant event, but only actions by the U.S. federal government regarding Eli Lilly count.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
How it unfolded
Every source in the order it published, with the odds on Eli Lilly at that moment. A dash means the source published before we started tracking prices.
- International homepageNovo investors call for dealmaking and new drugs—
- MarketWatchNovo Nordisk stock tumbles as Ozempic maker sets out 2030 goals—
- News FeedNovo sheds 13,000 jobs in a year—
- Bloomberg MarketsNovo Plunges as Investors Seek More Robust Sales Targets—
- STATSTAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work—
- QuartzNovo Nordisk stock sinks after 2030 growth plan fails to impress investors—
- STATSTAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more—
- Bloomberg MarketsAccenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround | Stock Movers—
- News FeedNovo’s prospects beyond weight-loss drugs look surprisingly lean—
- Bloomberg MarketsNovo Still Has Work to Do to Build Investor Confidence, CEO Says—
Show 10 later sources
- Bloomberg.comNovo CEO Says Drugmaker Has More to Do to Win Over Investors—
- STATSTAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program—
- STATSTAT+: Did the Trump administration just cut Novo a huge financial win?—
- News FeedOzempic-maker Novo open to upgrading US listing—
- FortuneU.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast—
- Bloomberg.comNovo Signs Delivery Deal With Nanexa Worth Up to $1.3 Billion7%
- MarketWatchAfter capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring7%
- CNBCNovo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s7%
- QuartzNovo Nordisk signed a $1.3 billion deal for technology to make longer-lasting obesity shots7%
- QuartzNovo Nordisk unterzeichnete einen 1,3 Milliarden Dollar schweren Vertrag für Technologie zur Herstellung von länger anhaltenden Injektionen gegen Fettleibigkeit.7%
- Current odds15%
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s CNBC ·
- Novo Signs Delivery Deal With Nanexa Worth Up to $1.3 Billion Bloomberg.com ·
- Ozempic-maker Novo open to upgrading US listing News Feed ·
- Novo CEO Says Drugmaker Has More to Do to Win Over Investors Bloomberg.com ·
- Novo Still Has Work to Do to Build Investor Confidence, CEO Says Bloomberg Markets ·
- Novo’s prospects beyond weight-loss drugs look surprisingly lean News Feed ·
Show 14 more sources
- Accenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround | Stock Movers Bloomberg Markets ·
- Novo Plunges as Investors Seek More Robust Sales Targets Bloomberg Markets ·
- Novo sheds 13,000 jobs in a year News Feed ·
- Novo investors call for dealmaking and new drugs International homepage ·
- Novo Nordisk unterzeichnete einen 1,3 Milliarden Dollar schweren Vertrag für Technologie zur Herstellung von länger anhaltenden Injektionen gegen Fettleibigkeit. Quartz
- Novo Nordisk signed a $1.3 billion deal for technology to make longer-lasting obesity shots Quartz
- After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring MarketWatch
- U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast Fortune
- STAT+: Did the Trump administration just cut Novo a huge financial win? STAT
- STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program STAT
- STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more STAT
- Novo Nordisk stock sinks after 2030 growth plan fails to impress investors Quartz
- STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work STAT
- Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals MarketWatch
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi Eli Lilly 15% +8
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- Novo Nordisk
- Eli Lilly
- Mike Doustdar
- Nanexa